

BIOMARIN PHARMACEUTICAL INC.

ISIN: US09061G1013 WKN: 09061G101 Asset Class: Stock

Company

2024/04/16 22:00:00

BIOMARIN

Price
90.87
USD

Difference  **-0.70% (-0.64)**



Contact Details

BIOMARIN
PHARMACEUTICAL INC.

Tel: +1-415-506-6700

--

Fax: +1-415-382-7889

770 Lindaro Street

Web:
<http://www.biomarin.com>

94901 San Rafael

E-mail:
customersupport@bmrn.com

Company Profile

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	2,956,088,000		2,751,457,000		2,274,385,000	
Common stock capital		189,000		186,000		184,000
Fixed assets	3,885,515,000		3,623,617,000		3,728,940,000	
Equity capital of a company		4,951,549,000		4,603,156,000		4,270,740,000
Cash and cash equivalents	755,127,000		724,531,000		587,276,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		1,177,024,000		588,884,000		539,822,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		713,030,000		1,183,034,000		1,192,763,000
Different income		-		-		-
Other liabilities		81,811,000		73,502,000		79,844,000
Total assets	6,841,603,000	6,841,603,000	6,375,074,000	6,375,074,000	6,003,325,000	6,003,325,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	3,401	3,082	3,045
Equity ratio	72.37%	72.21%	71.14%
Debt-equity ratio	38.17%	38.49%	40.57%

Others

	2023	2022	2021
Tax Expense Rate	11.09%	5.36%	14.96%

BIOMARIN PHARMACEUTICAL INC.

ISIN: US09061G1013 WKN: 09061G101 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	2,419,412,000	2,047,498,000	1,846,079,000
Net income	167,645,000	141,561,000	-64,080,000
EBIT	137,569,256	137,525,438	-65,722,489
Operating income before taxes	188,563,000	149,576,000	-75,350,000
Cash Flow	159,259,000	175,902,000	304,536,000
Net interest income	41,004,000	2,064,000	-4,855,000
Research and development expenses	746,773,000	649,606,000	628,793,000
Income taxes	20,918,000	8,015,000	-11,270,000
Result from investments in subsidiaries, associates and other	0	0	-
Revenues per employee	663,222	619,365	565,221

Board of Directors

Members of Management Board

Richard Meier	Chairman of Board of Directors
Athena Countouriotis	Member of Board of Directors
Dennis Slamon	Member of Board of Directors
Elaine Heron	Member of Board of Directors
May Kin Ho	Member of Board of Directors
V. Lawlis	Member of Board of Directors
Willard Dere	Member of Board of Directors
Barbara Bodem	Member of Board of Directors
David Pyott	Member of Board of Directors
Elizabeth Anderson	Member of Board of Directors
Jean-Jacques Bienaimé	Member of Board of Directors
Mark Alles	Member of Board of Directors
Mark Enyedy	Member of Board of Directors
Robert Hombach	Member of Board of Directors
Jean-Jacques Bienaimé	Chairman of Managing Board
Brinda Balakrishnan	Member of Executive Committee
C. Greg Guyer	Member of Executive Committee
Amy Wireman	Member of Executive Committee
Brian Mueller	Member of Executive Committee
G. Eric Davis	Member of Executive Committee
Henry J. Fuchs	Member of Executive Committee
Jeff Ajer	Member of Executive Committee
Philip Lo Scalzo	Member of Executive Committee